Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma

Abstract

Oral squamous cell carcinoma (OSCC) is associated with heavy smoking and drinking, but the molecular pathway of tumorigenesis is not understood. Inactivation of the p53 tumor suppressor gene is likely to play an important role since p53 mutation is frequently found. The p14ARF tumor suppressor gene is functionally linked to p53, because it is activated by oncogenes and causes p53-dependent growth arrest and apoptosis. The relationship between p14ARF and p53 inactivation has not been described for OSCC. We studied 25 cases of OSCC to determine if there is an inverse correlation between p53 mutation and p14ARF inactivation by homozygous deletion or mutation. p53 mutation was found in 16 of 25 cases (64%), including nine missense and seven truncating mutations. While all cases with missense mutations showed abnormal accumulation of p53 protein, there were also five carcinomas which showed increased p53 staining in the absence of mutation. p14ARF deletion or mutation was found in eight cases (32%), six of which also demonstrated p53 mutation. Our findings indicate that OSCC often involves loss of both p14ARF and p53 function and suggest that inactivation of these two tumor suppressor genes are not functionally equivalent during tumorigenesis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, Armand JP and Riou G. . 1995 Oncogene 10: 1217–1227.

  • Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A and Fraumeni Jr JF. . 1988 Cancer Res. 48: 3282–3287.

  • Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S and Liotta LA. . 1997 Science 278: 1481–1483.

  • Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, Correo R, Eby YJ, Ruppert JM and Sidransky D. . 1993 Cancer Res. 53: 4477–4480.

  • Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, Couch MJ, Forastiere AA and Sidransky D. . 1995 New Engl. J. Med. 332: 712–717.

  • Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W and Sidransky D. . 1996 Cancer Res. 56: 2488–2492.

  • Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B and Slamon DJ. . 1996 Oncogene 13: 1971–1981.

  • Chin L, Pomerantz J and DePinho RA. . 1998 Trends Biochem. Sci. 23: 291–296.

  • Erber R, Conradt C, Homann N, Enders C, Finckh M, Dietz A, Weidauer H and Bosch FX. . 1998 Oncogene 16: 1671–1679.

  • Field JK. . 1992 Eur. J. Cancer. Part B, Oral Oncology 28B: 67–76.

  • Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A and Van Meir EG. . 2000 Oncogene 19: 3816–3822.

  • Giaccia AJ and Kastan MB. . 1998 Genes Dev. 12: 2973–2983.

  • Hall PA and Lane DP. . 1994 J. Path. 172: 1–4.

  • Hartwell LH and Kastan MB. . 1994 Science 266: 1821–1828.

  • Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A and Collins VP. . 2000 Cancer Res. 60: 417–424.

  • Koch WM, Lango M, Sewell D, Zahurak M and Sidransky D. . 1999 Laryngoscope 109: 1544–1551.

  • Liloglou T, Scholes AG, Spandidos DA, Vaughan ED, Jones AS and Field JK. . 1997 Cancer Res. 57: 4070–4074.

  • Lohrum MAE, Ashcroft M, Kubbutat JHG and Vousden KH. . 2000 Curr. Biol. 10: 539–542.

  • Markl ID and Jones PA. . 1998 Cancer Res. 58: 5348–5353.

  • Mashberg A, Boffetta P, Winkelman R and Garfinkel L. . 1993 Cancer 72: 1369–1375.

  • Prives C and Hall PA. . 1999 J. Pathol. 187: 112–126.

  • Ruas M and Peters G. . 1998 Biochim. Biophys. Acta 1378: F115–F177.

  • Sanchez-Cespedes M, Reed AL, Buta M, Wu L, Westra WH, Herman JG, Yang SC, Jen J and Sidransky D. . 1999 Oncogene 18: 5843–5849.

  • Shahnavaz SA, Regezi JA, Bradley G, Dube ID and Jordan RC. . 2000 J. Pathol. 190: 417–422.

  • Sherr CJ. . 1998 Genes Dev. 12: 2984–2991.

  • Sherr CJ and Weber JD. . 2000 Curr. Opin. Genet. Dev. 10: 94–99.

  • Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH and Peters G. . 1998 EMBO J. 17: 5001–5014.

  • Xu L, Chen YT, Huvos AG, Zlotolow IM, Rettig WJ, Old LJ and Garin-Chesa P. . 1994 Diagn. Mol. Path. 3: 83–92.

  • Zhang Y and Xiong Y. . 1999 Mol. Cell. 3: 579–591.

Download references

Acknowledgements

This study was supported by grants from the Medical Research Council of Canada and the National Cancer Institute of Canada to S Benchimol, and the Conacher Head and Neck Cancer Research Laboratory. We wish to thank Drs D Brown and J Freeman, Department of Otolaryngology, the Toronto General Hospital and Mount Sinai Hospital, for their support of this study. We thank Mr James Ho for his capable technical assistance in histopathology.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bradley, G., Irish, J., MacMillan, C. et al. Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma. Oncogene 20, 654–658 (2001). https://doi.org/10.1038/sj.onc.1204131

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204131

Keywords

This article is cited by

Search

Quick links